UniProt ID | DAB2_HUMAN | |
---|---|---|
UniProt AC | P98082 | |
Protein Name | Disabled homolog 2 | |
Gene Name | DAB2 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 770 | |
Subcellular Localization | Cytoplasm. Cytoplasmic vesicle, clathrin-coated vesicle membrane. Membrane, clathrin-coated pit. Colocalizes with large insert-containing isoforms of MYO6 at clathrin-coated pits/vesicles. During mitosis is progressively displaced from the membrane a | |
Protein Description | Adapter protein that functions as clathrin-associated sorting protein (CLASP) required for clathrin-mediated endocytosis of selected cargo proteins. Can bind and assemble clathrin, and binds simultaneously to phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) and cargos containing non-phosphorylated NPXY internalization motifs, such as the LDL receptor, to recruit them to clathrin-coated pits. Can function in clathrin-mediated endocytosis independently of the AP-2 complex. Involved in endocytosis of integrin beta-1; this function seems to redundant with the AP-2 complex and seems to require DAB2 binding to endocytosis accessory EH domain-containing proteins such as EPS15, EPS15L1 and ITSN1. Involved in endocytosis of cystic fibrosis transmembrane conductance regulator/CFTR. Involved in endocytosis of megalin/LRP2 lipoprotein receptor during embryonal development. Required for recycling of the TGF-beta receptor. Involved in CFTR trafficking to the late endosome. Involved in several receptor-mediated signaling pathways. Involved in TGF-beta receptor signaling and facilitates phosphorylation of the signal transducer SMAD2. Mediates TFG-beta-stimulated JNK activation. May inhibit the canoniocal Wnt/beta-catenin signaling pathway by stabilizing the beta-catenin destruction complex through a competing association with axin preventing its dephosphorylation through protein phosphatase 1 (PP1). Sequesters LRP6 towards clathrin-mediated endocytosis, leading to inhibition of Wnt/beta-catenin signaling. May activate non-canonical Wnt signaling. In cell surface growth factor/Ras signaling pathways proposed to inhibit ERK activation by interrupting the binding of GRB2 to SOS1 and to inhibit SRC by preventing its activating phosphorylation at 'Tyr-419'. Proposed to be involved in modulation of androgen receptor (AR) signaling mediated by SRC activation; seems to compete with AR for interaction with SRC. Plays a role in the CSF-1 signal transduction pathway. Plays a role in cellular differentiation. Involved in cell positioning and formation of visceral endoderm (VE) during embryogenesis and proposed to be required in the VE to respond to Nodal signaling coming from the epiblast. Required for the epithelial to mesenchymal transition, a process necessary for proper embryonic development. May be involved in myeloid cell differentiation and can induce macrophage adhesion and spreading. May act as a tumor suppressor.. | |
Protein Sequence | MSNEVETSATNGQPDQQAAPKAPSKKEKKKGPEKTDEYLLARFKGDGVKYKAKLIGIDDVPDARGDKMSQDSMMKLKGMAAAGRSQGQHKQRIWVNISLSGIKIIDEKTGVIEHEHPVNKISFIARDVTDNRAFGYVCGGEGQHQFFAIKTGQQAEPLVVDLKDLFQVIYNVKKKEEEKKKIEEASKAVENGSEALMILDDQTNKLKSGVDQMDLFGDMSTPPDLNSPTESKDILLVDLNSEIDTNQNSLRENPFLTNGITSCSLPRPTPQASFLPENAFSANLNFFPTPNPDPFRDDPFTQPDQSTPSSFDSLKSPDQKKENSSSSSTPLSNGPLNGDVDYFGQQFDQISNRTGKQEAQAGPWPFSSSQTQPAVRTQNGVSEREQNGFSVKSSPNPFVGSPPKGLSIQNGVKQDLESSVQSSPHDSIAIIPPPQSTKPGRGRRTAKSSANDLLASDIFAPPVSEPSGQASPTGQPTALQPNPLDLFKTSAPAPVGPLVGLGGVTVTLPQAGPWNTASLVFNQSPSMAPGAMMGGQPSGFSQPVIFGTSPAVSGWNQPSPFAASTPPPVPVVWGPSASVAPNAWSTTSPLGNPFQSNIFPAPAVSTQPPSMHSSLLVTPPQPPPRAGPPKDISSDAFTALDPLGDKEIKDVKEMFKDFQLRQPPAVPARKGEQTSSGTLSAFASYFNSKVGIPQENADHDDFDANQLLNKINEPPKPAPRQVSLPVTKSTDNAFENPFFKDSFGSSQASVASSQPVSSEMYRDPFGNPFA | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Acetylation | ------MSNEVETSA ------CCCCCCCCC | 41.52 | 19413330 | |
2 | Phosphorylation | ------MSNEVETSA ------CCCCCCCCC | 41.52 | 22199227 | |
7 | Phosphorylation | -MSNEVETSATNGQP -CCCCCCCCCCCCCC | 28.92 | 25159151 | |
8 | Phosphorylation | MSNEVETSATNGQPD CCCCCCCCCCCCCCC | 21.42 | 27486199 | |
10 | Phosphorylation | NEVETSATNGQPDQQ CCCCCCCCCCCCCCC | 39.38 | 27486199 | |
24 | Phosphorylation | QAAPKAPSKKEKKKG CCCCCCCCHHHHCCC | 62.31 | 28842319 | |
34 | Ubiquitination | EKKKGPEKTDEYLLA HHCCCCCCCCHHHHH | 65.49 | - | |
38 | Phosphorylation | GPEKTDEYLLARFKG CCCCCCHHHHHHHCC | 15.15 | 27642862 | |
53 | Malonylation | DGVKYKAKLIGIDDV CCCEEEEEEECCCCC | 36.16 | 26320211 | |
53 | Ubiquitination | DGVKYKAKLIGIDDV CCCEEEEEEECCCCC | 36.16 | - | |
64 | Methylation | IDDVPDARGDKMSQD CCCCCCCCCCCCCHH | 62.31 | - | |
67 | Acetylation | VPDARGDKMSQDSMM CCCCCCCCCCHHHHH | 43.19 | 7672303 | |
67 | Ubiquitination | VPDARGDKMSQDSMM CCCCCCCCCCHHHHH | 43.19 | - | |
69 | Phosphorylation | DARGDKMSQDSMMKL CCCCCCCCHHHHHHH | 36.25 | 20873877 | |
72 | Phosphorylation | GDKMSQDSMMKLKGM CCCCCHHHHHHHHHH | 17.09 | 20873877 | |
77 | Ubiquitination | QDSMMKLKGMAAAGR HHHHHHHHHHHHCCC | 40.91 | - | |
98 | Phosphorylation | QRIWVNISLSGIKII CCEEEEEECCCEEEE | 15.98 | - | |
100 | Phosphorylation | IWVNISLSGIKIIDE EEEEEECCCEEEEEC | 31.51 | - | |
108 | Ubiquitination | GIKIIDEKTGVIEHE CEEEEECCCCCEECC | 47.00 | - | |
120 | Ubiquitination | EHEHPVNKISFIARD ECCCCCCEEEEEEEC | 39.70 | - | |
151 | Phosphorylation | HQFFAIKTGQQAEPL EEEEEEEECCCCCCE | 33.82 | 22817900 | |
163 | Methylation | EPLVVDLKDLFQVIY CCEEEEHHHHHHHHH | 48.17 | - | |
170 | Phosphorylation | KDLFQVIYNVKKKEE HHHHHHHHHCCCHHH | 18.29 | 25159151 | |
173 | Methylation | FQVIYNVKKKEEEKK HHHHHHCCCHHHHHH | 55.26 | - | |
193 | Phosphorylation | SKAVENGSEALMILD HHHHHHCCCEEEEEE | 31.14 | 25159151 | |
197 | Sulfoxidation | ENGSEALMILDDQTN HHCCCEEEEEEHHHC | 3.54 | 30846556 | |
203 | Phosphorylation | LMILDDQTNKLKSGV EEEEEHHHCCCCCCC | 41.12 | 28555341 | |
208 | Phosphorylation | DQTNKLKSGVDQMDL HHHCCCCCCCCHHHH | 55.26 | 23403867 | |
220 | Phosphorylation | MDLFGDMSTPPDLNS HHHCCCCCCCCCCCC | 42.37 | 25159151 | |
221 | Phosphorylation | DLFGDMSTPPDLNSP HHCCCCCCCCCCCCC | 32.00 | 25159151 | |
227 | Phosphorylation | STPPDLNSPTESKDI CCCCCCCCCCCCCCE | 40.26 | 25159151 | |
229 | Phosphorylation | PPDLNSPTESKDILL CCCCCCCCCCCCEEE | 53.35 | 25159151 | |
231 | Phosphorylation | DLNSPTESKDILLVD CCCCCCCCCCEEEEE | 37.80 | 25159151 | |
241 | Phosphorylation | ILLVDLNSEIDTNQN EEEEECCCCCCCCCC | 43.13 | 20873877 | |
245 | Phosphorylation | DLNSEIDTNQNSLRE ECCCCCCCCCCCCCC | 44.35 | 28060719 | |
249 | Phosphorylation | EIDTNQNSLRENPFL CCCCCCCCCCCCCCC | 21.02 | 27535140 | |
262 | Phosphorylation | FLTNGITSCSLPRPT CCCCCCCCCCCCCCC | 10.37 | 25627689 | |
264 | Phosphorylation | TNGITSCSLPRPTPQ CCCCCCCCCCCCCCC | 40.97 | 25159151 | |
301 | Phosphorylation | PFRDDPFTQPDQSTP CCCCCCCCCCCCCCC | 44.58 | 23663014 | |
306 | Phosphorylation | PFTQPDQSTPSSFDS CCCCCCCCCCCCHHH | 50.06 | 23663014 | |
307 | Phosphorylation | FTQPDQSTPSSFDSL CCCCCCCCCCCHHHC | 22.89 | 23663014 | |
309 | Phosphorylation | QPDQSTPSSFDSLKS CCCCCCCCCHHHCCC | 43.66 | 23663014 | |
310 | Phosphorylation | PDQSTPSSFDSLKSP CCCCCCCCHHHCCCC | 33.99 | 23663014 | |
313 | Phosphorylation | STPSSFDSLKSPDQK CCCCCHHHCCCCCCC | 35.37 | 23663014 | |
315 | Ubiquitination | PSSFDSLKSPDQKKE CCCHHHCCCCCCCCC | 64.99 | - | |
316 | Phosphorylation | SSFDSLKSPDQKKEN CCHHHCCCCCCCCCC | 38.72 | 23663014 | |
321 | Ubiquitination | LKSPDQKKENSSSSS CCCCCCCCCCCCCCC | 57.40 | - | |
324 | Phosphorylation | PDQKKENSSSSSTPL CCCCCCCCCCCCCCC | 32.46 | 23663014 | |
325 | Phosphorylation | DQKKENSSSSSTPLS CCCCCCCCCCCCCCC | 45.91 | 23663014 | |
326 | Phosphorylation | QKKENSSSSSTPLSN CCCCCCCCCCCCCCC | 28.29 | 23663014 | |
327 | Phosphorylation | KKENSSSSSTPLSNG CCCCCCCCCCCCCCC | 39.93 | 23663014 | |
328 | Phosphorylation | KENSSSSSTPLSNGP CCCCCCCCCCCCCCC | 35.67 | 23663014 | |
329 | Phosphorylation | ENSSSSSTPLSNGPL CCCCCCCCCCCCCCC | 30.14 | 23663014 | |
332 | Phosphorylation | SSSSTPLSNGPLNGD CCCCCCCCCCCCCCC | 40.73 | 23663014 | |
335 (in isoform 3) | Ubiquitination | - | 27.23 | - | |
342 | Phosphorylation | PLNGDVDYFGQQFDQ CCCCCCCHHHHHHHH | 14.95 | 23663014 | |
356 | Ubiquitination | QISNRTGKQEAQAGP HHHCCCCCHHHHCCC | 44.33 | - | |
367 | Phosphorylation | QAGPWPFSSSQTQPA HCCCCCCCCCCCCCC | 25.63 | 25159151 | |
368 | Phosphorylation | AGPWPFSSSQTQPAV CCCCCCCCCCCCCCE | 27.18 | 25627689 | |
369 | Phosphorylation | GPWPFSSSQTQPAVR CCCCCCCCCCCCCEE | 35.73 | 25159151 | |
371 | Phosphorylation | WPFSSSQTQPAVRTQ CCCCCCCCCCCEECC | 38.17 | 21712546 | |
390 | Phosphorylation | EREQNGFSVKSSPNP HHHHCCCCCCCCCCC | 29.99 | 25159151 | |
392 | Ubiquitination | EQNGFSVKSSPNPFV HHCCCCCCCCCCCCC | 43.98 | - | |
393 | Phosphorylation | QNGFSVKSSPNPFVG HCCCCCCCCCCCCCC | 49.20 | 25463755 | |
394 | Phosphorylation | NGFSVKSSPNPFVGS CCCCCCCCCCCCCCC | 23.99 | 25463755 | |
401 | Phosphorylation | SPNPFVGSPPKGLSI CCCCCCCCCCCCCEE | 32.50 | 19664994 | |
407 | O-linked_Glycosylation | GSPPKGLSIQNGVKQ CCCCCCCEECCCCHH | 30.69 | 30059200 | |
407 | Phosphorylation | GSPPKGLSIQNGVKQ CCCCCCCEECCCCHH | 30.69 | 27251789 | |
418 | Phosphorylation | GVKQDLESSVQSSPH CCHHHHHHHHCCCCC | 43.01 | 23663014 | |
419 | Phosphorylation | VKQDLESSVQSSPHD CHHHHHHHHCCCCCC | 18.14 | 23663014 | |
422 | Phosphorylation | DLESSVQSSPHDSIA HHHHHHCCCCCCCEE | 43.62 | 22167270 | |
423 | Phosphorylation | LESSVQSSPHDSIAI HHHHHCCCCCCCEEE | 14.79 | 22167270 | |
427 | Phosphorylation | VQSSPHDSIAIIPPP HCCCCCCCEEEECCC | 15.75 | 22167270 | |
436 | Phosphorylation | AIIPPPQSTKPGRGR EEECCCCCCCCCCCC | 44.14 | 25159151 | |
437 | Phosphorylation | IIPPPQSTKPGRGRR EECCCCCCCCCCCCC | 35.69 | 22817900 | |
438 | Ubiquitination | IPPPQSTKPGRGRRT ECCCCCCCCCCCCCC | 51.20 | - | |
448 | Phosphorylation | RGRRTAKSSANDLLA CCCCCCCCHHHHHHH | 32.02 | 20068231 | |
449 | Phosphorylation | GRRTAKSSANDLLAS CCCCCCCHHHHHHHH | 30.31 | 20873877 | |
456 | Phosphorylation | SANDLLASDIFAPPV HHHHHHHHCCCCCCC | 31.07 | 20068231 | |
464 | Phosphorylation | DIFAPPVSEPSGQAS CCCCCCCCCCCCCCC | 49.95 | 23663014 | |
467 | Phosphorylation | APPVSEPSGQASPTG CCCCCCCCCCCCCCC | 39.21 | 23663014 | |
471 | Phosphorylation | SEPSGQASPTGQPTA CCCCCCCCCCCCCCC | 18.33 | 23663014 | |
473 | Phosphorylation | PSGQASPTGQPTALQ CCCCCCCCCCCCCCC | 46.05 | 23663014 | |
477 | Phosphorylation | ASPTGQPTALQPNPL CCCCCCCCCCCCCCC | 31.92 | 23663014 | |
633 | Phosphorylation | AGPPKDISSDAFTAL CCCCCCCCCCCCHHC | 32.09 | 22199227 | |
634 | Phosphorylation | GPPKDISSDAFTALD CCCCCCCCCCCHHCC | 33.04 | 29214152 | |
638 | Phosphorylation | DISSDAFTALDPLGD CCCCCCCHHCCCCCC | 28.21 | 23186163 | |
646 | Ubiquitination | ALDPLGDKEIKDVKE HCCCCCCHHHHHHHH | 60.59 | - | |
652 | Ubiquitination | DKEIKDVKEMFKDFQ CHHHHHHHHHHHHCC | 54.30 | - | |
670 | Ubiquitination | PPAVPARKGEQTSSG CCCCCCCCCCCCCCC | 69.75 | - | |
674 | Phosphorylation | PARKGEQTSSGTLSA CCCCCCCCCCCHHHH | 22.13 | 21945579 | |
675 | Phosphorylation | ARKGEQTSSGTLSAF CCCCCCCCCCHHHHH | 26.85 | 21945579 | |
676 | Phosphorylation | RKGEQTSSGTLSAFA CCCCCCCCCHHHHHH | 38.90 | 21945579 | |
678 | O-linked_Glycosylation | GEQTSSGTLSAFASY CCCCCCCHHHHHHHH | 21.35 | 30059200 | |
678 | Phosphorylation | GEQTSSGTLSAFASY CCCCCCCHHHHHHHH | 21.35 | 21945579 | |
680 | Phosphorylation | QTSSGTLSAFASYFN CCCCCHHHHHHHHHH | 22.60 | 21945579 | |
684 | Phosphorylation | GTLSAFASYFNSKVG CHHHHHHHHHHHCCC | 24.65 | 21945579 | |
685 | Phosphorylation | TLSAFASYFNSKVGI HHHHHHHHHHHCCCC | 11.89 | 21945579 | |
688 | Phosphorylation | AFASYFNSKVGIPQE HHHHHHHHCCCCCHH | 20.86 | 21945579 | |
723 | O-linked_Glycosylation | KPAPRQVSLPVTKST CCCCCCEECCEECCC | 20.72 | 30059200 | |
723 | Phosphorylation | KPAPRQVSLPVTKST CCCCCCEECCEECCC | 20.72 | 25463755 | |
727 | O-linked_Glycosylation | RQVSLPVTKSTDNAF CCEECCEECCCCCCC | 19.82 | 30059200 | |
727 | Phosphorylation | RQVSLPVTKSTDNAF CCEECCEECCCCCCC | 19.82 | 25463755 | |
728 | Ubiquitination | QVSLPVTKSTDNAFE CEECCEECCCCCCCC | 52.14 | - | |
729 | O-linked_Glycosylation | VSLPVTKSTDNAFEN EECCEECCCCCCCCC | 31.46 | 30059200 | |
729 | Phosphorylation | VSLPVTKSTDNAFEN EECCEECCCCCCCCC | 31.46 | 30266825 | |
730 | O-linked_Glycosylation | SLPVTKSTDNAFENP ECCEECCCCCCCCCC | 34.52 | 30059200 | |
730 | Phosphorylation | SLPVTKSTDNAFENP ECCEECCCCCCCCCC | 34.52 | 30266825 | |
742 | Phosphorylation | ENPFFKDSFGSSQAS CCCCHHCCCCCCCHH | 31.90 | 28450419 | |
745 | Phosphorylation | FFKDSFGSSQASVAS CHHCCCCCCCHHHHC | 19.78 | 28450419 | |
746 | Phosphorylation | FKDSFGSSQASVASS HHCCCCCCCHHHHCC | 30.09 | 28450419 | |
749 | O-linked_Glycosylation | SFGSSQASVASSQPV CCCCCCHHHHCCCCC | 15.58 | 30059200 | |
749 | Phosphorylation | SFGSSQASVASSQPV CCCCCCHHHHCCCCC | 15.58 | 28450419 | |
752 | Phosphorylation | SSQASVASSQPVSSE CCCHHHHCCCCCCHH | 27.61 | 28450419 | |
753 | Phosphorylation | SQASVASSQPVSSEM CCHHHHCCCCCCHHH | 28.85 | 28450419 | |
757 | Phosphorylation | VASSQPVSSEMYRDP HHCCCCCCHHHHCCC | 27.54 | 28450419 | |
758 | Phosphorylation | ASSQPVSSEMYRDPF HCCCCCCHHHHCCCC | 26.98 | 28450419 | |
761 | Phosphorylation | QPVSSEMYRDPFGNP CCCCHHHHCCCCCCC | 14.07 | 28450419 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
24 | S | Phosphorylation | Kinase | PRKCB | P05771-2 | GPS |
24 | S | Phosphorylation | Kinase | PRKCD | Q05655 | GPS |
24 | S | Phosphorylation | Kinase | PRKCG | P05129 | GPS |
24 | S | Phosphorylation | Kinase | PKC-FAMILY | - | GPS |
24 | S | Phosphorylation | Kinase | PKC_GROUP | - | PhosphoELM |
723 | S | Phosphorylation | Kinase | CAMK2G | Q13555 | PSP |
723 | S | Phosphorylation | Kinase | ROCK2 | O75116 | PSP |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of DAB2_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of DAB2_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-394 AND SER-401, ANDMASS SPECTROMETRY. | |
"Automated phosphoproteome analysis for cultured cancer cells by two-dimensional nanoLC-MS using a calcined titania/C18 biphasic column."; Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.; Anal. Sci. 24:161-166(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-151; TYR-170 ANDSER-401, AND MASS SPECTROMETRY. | |
"A probability-based approach for high-throughput proteinphosphorylation analysis and site localization."; Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; Nat. Biotechnol. 24:1285-1292(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-393; SER-394 ANDSER-401, AND MASS SPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-342; SER-393 ANDSER-394, AND MASS SPECTROMETRY. | |
"Large-scale characterization of HeLa cell nuclear phosphoproteins."; Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,Li J., Cohn M.A., Cantley L.C., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-221; SER-227 ANDSER-401, AND MASS SPECTROMETRY. |